Salivary Oxytocin as a Biomarker of Psychedelic Treatment (PAPOXT_MDD)

University of Geneva, Switzerland

Status: Invitation-only

Conditions: Major Depressive Disorder (MDD)

Study type: Observational

Funder types: Other

Identifiers

NCT07345858

BASEC ID 2025-02092

Details and patient eligibility

About

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >=18 years-old
• MDD defined by DSM-V criteria, and resistant to treatment
• Ongoing classical psychotherapeutic treatment
• Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).

Exclusion criteria

• Psychotic or bipolar disorder
• High suicidal risk
• Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders
• Pregnancy or breastfeeding.